InsiderTrades

Form 4 for ARTV Artiva Biotherapeutics, Inc.

Accepted 2025-12-12 00:00:00 ET · period of report 2025-12-12 · accession 0001193125-25-317980 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-12-12 2025-12-12 ARTV Aslan Fred Pres, CEO, Dir A - Grant $0.00 +869.1K 1.21M +253% $0
DM 2025-12-12 2025-12-12 ARTV Aslan Fred Pres, CEO, Dir D - Sale to Iss — -869.1K 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-12-12 A A 869,136 $0.00 1,213,135 D — — (F1) Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs"). (F2) On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I.
2 Derivative Employee Stock Option (Right to Buy) 2025-12-12 D D 51,463 — 0 D $5.01 · — to 2030-12-17 51,463 Common Stock (F2) On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. (F3) 25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
3 Derivative Employee Stock Option (Right to Buy) 2025-12-12 D D 257,319 — 0 D $5.01 · — to 2030-12-17 257,319 Common Stock (F2) On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. (F4) 25% of the shares vest on January 1, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
4 Derivative Employee Stock Option (Right to Buy) 2025-12-12 D D 26,450 — 0 D $5.18 · — to 2034-01-23 26,450 Common Stock (F2) On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. (F5) Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts.
5 Derivative Employee Stock Option (Right to Buy) 2025-12-12 D D 113,999 — 0 D $13.47 · — to 2034-05-01 113,999 Common Stock (F2) On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. (F6) 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.
6 Derivative Employee Stock Option (Right to Buy) 2025-12-12 D D 319,331 — 0 D $12.00 · — to 2034-07-17 319,331 Common Stock (F2) On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. (F6) 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.
7 Derivative Employee Stock Option (Right to Buy) 2025-12-12 D D 100,577 — 0 D $5.01 · — to 2031-02-23 100,577 Common Stock (F2) On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. (F3) 25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.